Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,724 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 9,801 · Balance 109,068 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 4,344 · Balance 104,724 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 83,602 |
Reported balance
After 2026-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-30 · Exercise / conversion · Disposed 9,801 · Balance 83,602 F1: Represents shares acquired on vesting and settlement of restricted stock units. F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 62,815 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 62,815 F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 2, 2021 21:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,310 | $5.89 | $13,605.90 |
DisclosureSEC source: 0001654954-21-007593 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,972.8 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 7,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007593 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,282.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 11,929 | $16.90 | $201,600.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 5 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 16,384 | $16.44 | $269,352.96 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 4 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,596 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 29,996 | $15.12 | $453,539.52 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 3 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,980 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 24,224 | $14.09 | $341,316.16 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 2 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,976 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 42,467 | $13.30 | $564,811.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,200 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 63,060 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000913 · section16.xml · derivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,231 Underlying: Common Stock · 63,060 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024) Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 23:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000913 · section16.xml · derivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2021 and 1/48th monthly on the last day of each month thereafter. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000159 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,171 Underlying: Common Stock · 6,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,327 | $6.12 | $14,241.24 |
DisclosureSEC source: 0001654954-21-000159 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,399.8 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:40 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000159 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,726.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 111,753 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001654954-20-001794 · section16.xml · derivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,753 Underlying: Common Stock · 111,753 shares Expires 2030-01-31 F2 · derivative.exercise_date: Stock options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 26,895 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-001794 · section16.xml · derivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,895 Underlying: Common Stock · 26,895 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. F1 · derivative.expiration_date: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 125,000 | $8.00 | $1,000,000.00 |
DisclosureSEC source: 0001654954-19-014150 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer · 10% owner O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,667 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| August 09, 2018 Filed Sep 27, 2018 22:35 UTC | Monopar Therapeutics NONE · Entity 5152 | GrantStock options · Derivative | 145,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010574 · section16.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,500 Underlying: Common stock · 145,500 shares Expires 2028-08-08 F3 · derivative.exercise_date: Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.